Answers are grounded in this paper and cite their sources.
Shows improved patient outcomes in FLT3-ITD+ acute myeloid leukemia, suggesting effective management strategies.
-ITD+ AML with quizartinib may ultimately improve patient outcomes in this highly challenging malignancy.
No takes yet. Share an insight, caveat, or question.
Horsch et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: